--- title: "Vera Therapeutics to Present ORIGIN Phase 3 Atacicept Data for IgA Nephropathy at ASN Kidney Week 2025" description: "Vera Therapeutics Inc. will present data from the ORIGIN Phase 3 clinical trial of atacicept for IgA nephropathy at ASN Kidney Week 2025. An investor call and webcast is scheduled for November 6, 2025" type: "news" locale: "en" url: "https://longbridge.com/en/news/262236422.md" published_at: "2025-10-22T12:00:12.000Z" --- # Vera Therapeutics to Present ORIGIN Phase 3 Atacicept Data for IgA Nephropathy at ASN Kidney Week 2025 > Vera Therapeutics Inc. will present data from the ORIGIN Phase 3 clinical trial of atacicept for IgA nephropathy at ASN Kidney Week 2025. An investor call and webcast is scheduled for November 6, 2025, at 4:30 PM ET to review the trial results, which will be presented earlier that day during the morning plenary session. A replay of the webcast will be available for 90 days on the company's website. Vera Therapeutics Inc. has announced that it will host an investor call and webcast on November 6, 2025, at 4:30 PM ET to review data from the ORIGIN Phase 3 clinical trial of atacicept for the treatment of IgA nephropathy (IgAN). The results of this trial will be presented earlier that day during the morning plenary session at the American Society of Nephrology (ASN) Kidney Week 2025. A replay of the webcast will be available for 90 days on the Vera Therapeutics website. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vera Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9549913-en) on October 22, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) ### Related Stocks - [VERA.US - Vera Therapeutics](https://longbridge.com/en/quote/VERA.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Vera Therapeutics 股價大漲，因美國食品藥品監督管理局（FDA）接受其腎病藥物的優先審查 | Vera Therapeutics 的股票在盤前交易中上漲了 24%，達到 57.59 美元，此次上漲是因為美國 FDA 接受了其藥物 atacicept 的優先審查，該藥物旨在治療 IgA 腎病，這是一種嚴重的腎臟疾病。FDA 的決定預計 | [Link](https://longbridge.com/en/news/271790947.md) | | Maze Therapeutics 強調即將發佈的 MZE829 腎臟數據，並在峯會上制定 MZE782 的第二階段計劃 | Maze Therapeutics（納斯達克股票代碼：MAZE）正在推進一種以基因為驅動的藥物開發方法，專注於腎臟和代謝疾病。首席執行官 Jason Coloma 強調了兩個關鍵項目：MZE829 用於 APOL1 介導的腎臟疾病，臨牀數據 | [Link](https://longbridge.com/en/news/275972996.md) | | 公共財產投資 ASA 公司更新了他們的財務日曆 | Public Property Invest ASA 將於 2025 年 2 月 25 日 07:00 CET 發佈其 2025 財年第四季度財務業績。隨後將在 09:30 CET 舉行網絡直播演示，包括問答環節。此公告是他們財務日曆更新的 | [Link](https://longbridge.com/en/news/276312893.md) | | 邀請參加 2025 年第四季度業績發佈會的網絡直播 | Ocean Yield AS 將於 2026 年 2 月 26 日 09:00 CET 發佈其 2025 年第四季度財務業績。債券持有人和相關方被邀請參加網絡直播。該信息受挪威證券交易法的披露要求約束。如有查詢，請聯繫首席執行官 Andre | [Link](https://longbridge.com/en/news/276316727.md) | | Evolveum 將在 2026 年加特納身份和訪問管理峯會上展示人工智能驅動的身份治理與管理應用程序入駐加速 | Evolveum，開源 IGA 平台 midPoint 背後的公司，將於 2026 年 3 月 9 日至 10 日在倫敦的 Gartner IAM 峯會上展示其基於人工智能的應用程序入駐助手 midPilot。首席產品官 Pavol Med | [Link](https://longbridge.com/en/news/276321576.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.